Protein Sciences specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health by effectively responding to the changing world through the creation of innovative vaccines and biopharmaceuticals.

Flublok, the world's first recombinant protein-based seasonal influenza vaccine, is now approved in the U.S. for adults 18-49 years old.

---

Latest News